Search clinical trials for: GBP510 adjuvanted with AS03 (RBD 25μg/dose)- Stage 2

Total 22 results

SK Bioscience Co., Ltd.
GlaxoSmithKline; Coalition for Epidemic Preparedness Innovations

Active, not recruiting

Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)

COVID-19 (Healthy Volunteers)

Korea, Republic of
SK Bioscience Co., Ltd.
Coalition for Epidemic Preparedness Innovations

Completed

Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)

COVID-19 (Healthy Volunteers)

Korea, Republic of
Korea University Guro Hospital
Korean Center for Disease Control and Prevention

Active, not recruiting

Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)

COVID-19 (Healthy Volunteers)

Korea, Republic of
SK Bioscience Co., Ltd.
GlaxoSmithKline; International Vaccine Institute; Coalition for Epidemic Preparedness...

Completed

Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)

Covid19

Thailand, Korea, Republic of, New Zealand, Philippines, Ukraine, Vietnam
SK Bioscience Co., Ltd.
GlaxoSmithKline; International Vaccine Institute; Coalition for Epidemic Preparedness...

Active, not recruiting

Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted With AS03 in Adults Aged 18 Years and Older

COVID-19

Colombia, Nepal
SK Bioscience Co., Ltd.

Completed

Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)

COVID-19 (Healthy Volunteers)

Korea, Republic of
GlaxoSmithKline

Recruiting

A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years

Hepatitis B

Germany, United Kingdom, Belgium
University of Oxford
Wellcome Trust

Recruiting

A Controlled Human Vivax Malaria Infection Study Through Inoculation of Infected Erythrocytes (MIST2)

Plasmodium Vivax Infection

Thailand
University Hospital, Antwerp

Not yet recruiting

Standardised Drug Provocation Testing in Perioperative Hypersensitivity

Hypersensitivity | Anaphylaxis | Allergic Reaction | Perioperative Complication | Immediate Hypersensitivity | Hypersensitivity, Drug | Anaphylactic Reaction

Belgium
Far Eastern Memorial Hospital
Research Ethics Review Committee

Unknown

Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients

Quality of Life | Percentage of Annual Acute Exacerbation

Taiwan
Medical College of Wisconsin

Active, not recruiting

Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Peking Union Medical College Hospital

Recruiting

Dexmedetomidine and Sufentanil Effect in PCA on Pediatric Patients Undergoing Scoliosis Surgery (DEX)

Dexmedetomidine

China
Memorial Sloan Kettering Cancer Center
Tufts Medical Center; Lahey Clinic

Completed

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Multiple Myeloma

United States
Paraskevi Matsota

Completed

A Comparison Study of Patient Controlled Epidural Analgesia (PCEA) With and Without Basal Infusion Using Ropivacaine 0,15% and Fentanyl μg/ml for Pain Relief in Labor, Assessment of Efficacy and Maternal Satisfaction.

Labor Pain

Greece
AstraZeneca

Completed

Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®) (ECLIPSEIII)

Hypertriglyceridemia

United States
University of Texas Southwestern Medical Center

Completed

Pain Relief Effects on Length of Labor

Labor Pain

United States
Jonsson Comprehensive Cancer Center
California Institute for Regenerative Medicine (CIRM)

Terminated

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT)

Sarcoma | Unresectable Malignant Neoplasm | Locally Advanced Malignant Neoplasm | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive

United States
Children's Oncology Group
National Cancer Institute (NCI); EsPhALL Network/ BFM Study Group

Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

United States, Canada, Puerto Rico, Australia, Finland, New Zealand, Saudi Arabia, Germany, Austria, Belgium, Chile, Czechia, France, Italy, Netherlands, Sweden, Switzerland, Hong Kong, Israel
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Childhood T Acute Lymphoblastic Leukemia

United States, Canada, Australia, New Zealand
National Cancer Institute (NCI)

Completed

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

United States, Canada, Australia, New Zealand, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Primary Mediastinal Large B-Cell Lymphoma

United States, Canada, Australia, Puerto Rico

Search clinical trials for: GBP510 adjuvanted with AS03 (RBD 25μg/dose)- Stage 2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations